Trial Profile

An investigator-initiated, open-label, phase II study of the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Aug 2022 New trial record
15 Aug 2022 According to a Short Wave Pharma media release, the trial has been approved by the Israeli Ministry of Health and is preparing for participant recruitment.
15 Aug 2022 According to a Short Wave Pharma media release, the company has entered into a Clinical Trial Agreement with the Sheba Fund for Health Services and Research (the "Fund") and with Dr. Eitan Gur, Principal Investigator and head of the Sheba Medical Center Department for Eating Disorders (Center) and Mr Yoel Golbert, Co-Investigator at the Center. Shortwave will be the exclusive commercial partner for the trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com